Contribution of social and demographic parameters to the long-term survival prognosis of chronic myeloid leukemia patients

Introduction. Therapy of chronic myeloid leukemia (CML) for the majority of patients is associated with continuous lifelong drug intake. Irregular drug intake greatly increases the risk of CML progression and death. It is still not well understood to what extent social and demographic factors infl uence the long-term consequences of CML therapy.

Aim — to determine the prognostic value of social parameters like marital status and education level in comparison with standard risk factors for the course of the disease.

Materials and methods. A multifactorial data analysis of the presented sociodemographic parameters was carried out on a cohort of CML patients included in the multicenter observational study “Russian Registry for the Treatment of Chronic Myeloid Leukemia in Routine Clinical Practice”. The database of the study conducted in Russia in 2011–2016 includes records of 12160 patients with CML. To analyze the register data, we used classical methods of event analysis implemented in the SAS 9.4 package.

Results. A large volume of data with a high level of significance showed that educational level and marital status have a great prognostic value in assessing the long-term results of therapy in patients with CML, comparable to known risk factors. The contribution of these signs was evaluated and analyzed taking into account such known factors as age, ELTS index, and region or clinic where the patient was observed and treated. Thus, low educational qualifications and marital status “divorced” or “widowed” demonstrated significant and independent risk factors that negatively affect the life expectancy of patients with CML Conclusion. The discovered phenomenon is key in long-term survival and can be explained by the indirect infl uence of social-demographic parameters through adherence behavior of CML patients. Higher level of education proved to be a favorable factor while a widowed/divorced marital status was found to be an unfavorable factor of OS prognosis. General clinic, age related interpretations, and regional features were also tested and did not find any confirmation.

1. Druzhinin V. Family Psychology. 3rd edition. Ekaterinburg: Delovaya kniga; 2000. (in Russian).

2. Obozov N. Psychology of interpersonal relations. Kiev: Lybid; 1990. (in Russian).

3. Argyle M. Psychology of happiness. Moscow; 1990. (in Russian).

4. Antonov A. Microsociology of the family. Moscow: Publishing House “InfraM”; 1998. (in Russian).

5. Deininger M.W., Goldman J.M., Melo J.V. The molecular biology of chronic myeloid leukemia. Blood. 2000; 96(10): 3343–56.

6. Turkina A.G., Zaritsky A.Yu., Shuvaev V.A., et al. Clinical guidelines for the diagnosis and treatment of chronic myeloid leukemia. Klinicheskaya oncogematologiya. 2017; 10(3): 294–316. DOI: 10.21320/2500-2139-2017-10-3-294-316. (in Russian).

7. Goldman J.M. Chronic myeloid leukemia: Molecular targeting as a basis for therapy. Rev Clin Exp Hematol. 2004; 7: 64–72.

8. Gambacorti-Passerini C., Antolini L., Mahon F.X., et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011; 103(7): 553–61. DOI: 10.1093/jnci/djr060.

9. Bower H., Björkholm M., Dickman P.W., et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016; 34(24): 2851–7. DOI: 10.1200/JCO.2015.66.2866.

10. Huang X., Cortes J., Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012; 118(12): 3123–7. DOI: 10.1002/cncr.26679.

11. Lauseker M., Gerlach R., Tauscher M., Hasford J. Improved survival boosts the prevalence of chronic myeloid leukemia: Predictions from a population-based study. J Cancer Res Clin Oncol. 2016; 142(7): 1441–7. DOI: 10.1007/s00432-016-2155-y.

12. Shukhov O.A., Turkina A.G., Chelysheva E.Yu., et al. Long-term results of therapy with tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the early and late chronic phase. Klinicheskaya oncogematologiya. 2016; 9(3): 368. (in Russian).

13. Abdulkadyrov K.M., Shuvaev V.A., Martynkevich I.S., et al. Chronic myelogenous leukemia: Many years of experience in targeted therapy. Klinicheskaya oncogematologiya. 2016; 9(1): 54–60. (in Russian).

14. Castagnetti F., Gugliotta G., Breccia M., et al. GIMEMA CML Working Party. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia. 2015; 29(9): 1823–31. DOI: 10.1038/leu.2015.152.

15. Stagno F., Stella S., Spitaleri A., et al. Imatinib mesylate in chronic myeloid leukemia: Frontline treatment and long-term outcomes. Expert Rev Anticancer Ther. 2016; 16(3): 273–8. DOI: 10.1586/14737140.2016.1151356.

16. Lazorko N.S., Lomaia E.G., Romanova E.G., et al. Second-generation tyrosine kinase inhibitors and their toxicity in patients in the chronic phase of chronic myeloid leukemia. Klinicheskaya oncogematologiya. 2015; 8: 302–8. (in Russian).

17. Valent P., Hadzijusufovic E., Hoermann G., et al. Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. Leuk Res. 2017; 59: 47–54. DOI: 10.1016/j.leukres.2017.05.008.

18. Shuvaev V.A., Fominykh M.S., Martynkevich I.S., et al. Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients. Onkogematologiya. 2013; 4: 7–12. (in Russian).

19. Lima L., Bernal-Mizrachi L., Saxe D., et al. Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents,and beyond. Cancer. 2011; 117(6): 1245–52. DOI: 10.1002/cncr.25678.

20. Vrijens B., De Geest S., Hughes D.A., et al. A new taxonomy for describing and defi ning adherence to medications. Br J Clin Pharmacol. 2012; 73(5): 691–705. DOI: 10.1111/j.1365-2125.2012.04167.x.

21. Noens L., van Lierde M.A., De Bock R., et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study. Blood. 2009; 113(22): 5401–11. DOI: 10.1182/blood-2008-12-196543.

22. Marin D., Bazeos A., Mahon F.X., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010; 28(14): 2381–8. DOI: 10.1200/JCO.2009.26.3087.

23. Ruddy K., Mayer E., Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009; 59(1): 56–66. DOI: 10.3322/caac.20004.

24. Effi cace F., Baccarani M., Rosti G., et al. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: An observational patient-centered outcome study. Br J Cancer. 2012; 107(6): 904–9. DOI: 10.1038/bjc.2012.348.

25. Partridge A., Avorn J., Wang P., Winer E. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Instit. 2002; 94(9): 652–61. DOI: 10.1093/jnci/94.9.652.

26. Gordillo V., del Amo J., Soriano V., González-Lahoz J. Sociodemographic and psychological variables infl uencing adherence to antiretroviral therapy. AIDS. 1999; 13(13): 1763–9. DOI: 10.1097/00002030-199909100-00021.

27. Jackevicius C.A., Mamdani M., Tu J.V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002; 288(4):462–7. DOI: 10.1001/jama.288.4.462.

28. Krousel-Wood M., Thomas S., Muntner P., Morisky D. Medication adherence:A key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol. 2004; 19(4): 357–62. DOI: 10.1097/01. hco.0000126978.03828.9e.

29. Kripalani S., LeFevre F., Phillips C.O., et al. Defi cits in communication and information transfer between hospital-based and primary care physicians: Implications for patient safety and continuity of care. JAMA. 2007; 297(8): 831–41. DOI: 10.1001/jama.297.8.831.

30. Effi cace F., Baccarani M, Breccia M., et al. GIMEMA. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood. 2011; 118(17): 4554–60. DOI: 10.1182/blood-2011-04-347575.

31. Eliasson L. Treatment adherence in chronic myeloid leukemia: A systematic review of the literature. Clin Pract. 2012; 9(1): 87–100.

32. Rychter A., Jerzmanowski P., Hołub A., et al. Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors. Med Oncol. 2017; 34(6): 104. DOI: 10.1007/s12032-017-0958-6.

33. Boons C.C.L.M., Harbers L., Timmers L., et al. Needs for information and reasons for (non)adherence in chronic myeloid leukaemia: Be aware of social activities disturbing daily routines. Eur J Haematol. 2018. DOI: 10.1111/ejh.13155.

34. Туркина А.Г., Новицкая Н.В., Голенков А.К. и др. Регистр больных хроническим миелолейкозом в Российской Федерации: от наблюдательного исследования к оценке эффективности терапии в клинической практике. Клиническая онкогематология. 2017; 10(3): 390–401. DOI: 10.21320/2500-2139-2017-10-3-390-401.

35. The Good Clinical Practice (GCP). https://gcp.nidatraining.org

36. Baccarani M., Deininger M.W., Rosti G., et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122(6): 872–84. DOI: 10.1182/blood-2013-05-501569.

37. Pfi rrmann M., Baccarani M., Saussele S., et al. Prognosis of long-term survival considering disease-specifi c death in patients with chronic myeloid leukemia. Leukemia. 2016; 30(1): 48–56. DOI: 10.1038/leu.2015.261.

38. https://www.leukemia-net.org/leukemias/cml/elts_score/pertensive patients. Curr Opin Cardiol. 2004; 19(4): 357–62. DOI: 10.1097/01.hco.0000126978.03828.9e.